Back

The Site of Intracellular Metabolism May Be a Relevant Drug Target in Dry AMD

September 09, 2015

In the May/June cover story of Retina Today, Scott W. Cousins, MD, offers insights into how our investigational mitochondrial targeted drug Ocuvia (MTP-131) may help treat age-related macular degeneration (AMD).

AMD accounts for 54% of all blindness in Americans of European ancestry and 5% globally. It is the most common cause of blindness in the elderly. An estimated 11 million Americans have AMD, and that number is expected to double to approximately 22 million by 2050. Currently, there are no FDA-approved treatments for AMD.

In the Retina Today article, Dr. Cousins — who recently spoke at our Mitochondrial Science and Medicine Series — explores how mitochondrial dysfunction that stems from environmental toxins, such as smoking and pollution, may be an important risk factor in and cause of dry AMD. In laboratory models, Ocuvia appears to prevent the mitochondrial dysfunction in the retinal pigment epithelium that might be a causative factor in AMD. This critical need for treatment of AMD and promising pre-clinical data led to the development of a Phase 1/2 trial by Jeffrey Heier, MD to study the safety and tolerability of Ocuvia in patients with diabetic macular edema and dry AMD.

To learn more, check out the full Retina Today story, “Role of Mitochondrial Dysfunction in Dry Age-Related Macular Degeneration.”

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Rachel Frank, 212-362-1200
IR@stealthbt.com